Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide

We present a case of a 68-year-old man with metastatic small bowel neuroendocrine tumor who underwent 4 cycles of peptide receptor radionuclide therapy with Lu-177-DOTATATE. For his first 3 cycles, therapy was performed approximately 4 weeks after his last dose of octreotide LAR. Because of miscommunication in scheduling, his fourth cycle was performed only 48 hours after his last full dose of octreotide LAR. Despite this, we found that the tumoral uptake was not reduced at all, which may add to the increasing evidence on the nonnecessity of stopping somatostatin analogs before peptide receptor radionuclide therapy.

Automated summary

This case report presents a 68-year-old man with metastatic small bowel neuroendocrine tumor who underwent peptide receptor radionuclide therapy. Despite a miscommunication in scheduling, the tumoral uptake was not reduced after the fourth cycle of therapy, suggesting that stopping somatostatin analogs before the therapy may not be necessary.